D. Michael Ackermann

D. Michael Ackermann is an accomplished academic and industry professional currently serving as an Adjunct Professor in the Department of Bioengineering at Stanford University since January 2023. He also holds the position of Director of Biotechnology at the Stanford Byers Center for Biodesign, a role he has maintained since May 2022. His extensive background includes co-instructing the Biodesign Innovation Course at Stanford from September 2017 to May 2022.1

Education and Early Career

Ackermann earned his Bachelor of Engineering in Biomedical Engineering from Vanderbilt University (2000-2004) and both his Master of Science and Ph.D. in Biomedical Engineering, specializing in Neuroengineering, from Case Western Reserve University (2004-2009). He furthered his training with a Biodesign Fellowship at Stanford (2010-2011) and served as a Vision Research Fellow at Stanford (2011-2012).1

Professional Experience

In addition to his academic roles, Ackermann has founded and led several companies:

• Osanni Bio, where he serves as CEO since October 2022.
• Presidio Medical, Inc., where he was CEO from September 2017 to August 2021 and is currently a board member.
• He has held various leadership positions in other biotech firms, including Tarsus Pharmaceuticals and Oyster Point Pharma, demonstrating a strong entrepreneurial spirit in the biotechnology sector.1

Contributions to Bioengineering

Ackermann's work focuses on advancing biotechnology and neuroengineering, contributing significantly to innovation in medical devices and therapies. His dual role in academia and industry positions him as a key figure in bridging research and practical applications in bioengineering.1